To investigate the correlation between LAPTM5 and NASH, we firstly determined the protein expression of LAPTM5 in the livers of human subjects without steatosis or with NASH, the hepatic LAPTM5 protein levels were found to be significantly down-regulated in the NASH patients than in their non-NASH counterparts (Fig. 1g and Supplementary Fig. 1a, b). This evidence concerns the gene LAPTM5 and metabolic dysfunction-associated steatohepatitis.